Ensem Therapeutics, A Cbc Group-Incubated Biopharma Company, Raises $67 Million In Series A Financing To Develop Small Molecule Medicines For Difficult-To-Drug Targets
Amount Raised
$67 Million
Round Type
Series A
BostonBiotechnologySoftwareData And AnalyticsHealth CareScience And EngineeringDescription
ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc., and CBC Group, bringing the series A total to $67 million.
Quick answer
Ensem Therapeutics raised $67 Million in a Series A round, dated April 6, 2022. Ensem Therapeutics is based in Boston, Massachusetts, United States.
- How much did Ensem Therapeutics raise?
- Ensem Therapeutics raised $67 Million in a Series A round on April 6, 2022.
- What does Ensem Therapeutics do?
- ENSEM is a pioneering drug discovery and development company that leverages its unique Kinetic EnsembleTM platform to develop innovative small molecule precision medicines for oncology, with potential expansion into..
- Where is Ensem Therapeutics based and how big is it?
- Ensem Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at Ensem Therapeutics?
- Fundz holds 1 contact at Ensem Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Data And Analytics and Science And Engineering around the same time
Companies in the same sectors as Ensem Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- IMPLICITY raised $23M (Funding Round) on April 27, 2022.
- Zephyr AI, Inc. raised $18M on April 4, 2022.
- Zephyr AI, Inc. raised $19M (Seed) on March 30, 2022.
- Nucleai raised $33M (Series B) on March 22, 2022.
- Sequentify raised $7M (Funding Round) on May 10, 2022.
- Engimmune Therapeutics raised an undisclosed amount (Seed) on May 3, 2022.
Who to call at Ensem Therapeutics, and when
A new round usually means Ensem Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ensem Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ensem Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ensem Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ensem Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEnsem Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.